Clinical Trial Update: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) [Phase 1, Phase 2]

View source ↗

Summary

PMV Pharmaceuticals is evaluating PC14586 in a Phase 1/2 trial for advanced solid tumors harboring the TP53 Y220C mutation. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Small Cell Lung Cancer

Drugs mentioned

• PC14586

Snippet

Sponsor: PMV Pharmaceuticals, Inc | Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1, Phase 2 | Status: RECRUITING